09.20.2019 - By MDedge
Prasugrel bests ticagrelor in ACS in surprise findings ISAR-REACT 5 was the first-ever direct head-to-head look at two potent P2Y12 inhibitors in this setting. European cholesterol guidelines push LDL targets below 55 mg/dL PCSK-9 inhibitors are elevated to a top-tier recommendation in very-high-risk patients. Drug doses for heart failure could possibly be halved for women Women reached the highest level of drug efficacy at half the doses of ACE inhibitors or ARBs and beta-blockers. Post-MI angina in stable patients flags high risk The angina finding should immediately influence practice, expert says. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: [email protected] Interact with us on Twitter: @MDedgeCardio